Posaconazole: an oral triazole with an extended spectrum of activity (Q28291282)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Posaconazole: an oral triazole with an extended spectrum of activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Erik J Rachwalski

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Jeffrey T Wieczorkiewicz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

19 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

Annals of Pharmacotherapy

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

1429-1438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

Posaconazole: a broad-spectrum triazole antifungal

12 January 2020

cites work

1 reference

Posaconazole: a new broad-spectrum antifungal agent

21 January 2018

1 reference

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

21 January 2018

1 reference

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis

21 January 2018

1 reference

Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact

21 January 2018

1 reference

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

21 January 2018

1 reference

Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs

21 January 2018

1 reference

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection

21 January 2018

1 reference

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

21 January 2018

1 reference

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

21 January 2018

1 reference

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles

21 January 2018

1 reference

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients

21 January 2018

1 reference

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

21 January 2018

1 reference

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers

21 January 2018

1 reference

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of antifungals

21 January 2018

1 reference

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin

21 January 2018

1 reference

Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases

21 January 2018

1 reference

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.

21 January 2018

1 reference

Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy

21 January 2018

1 reference

Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole

21 January 2018

1 reference

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

21 January 2018

1 reference

Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient

21 January 2018

1 reference

Activity of posaconazole in the treatment of central nervous system fungal infections

21 January 2018

1 reference

A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole

21 January 2018

1 reference

Refractory coccidioidomycosis treated with posaconazole

21 January 2018

1 reference

Posaconazole therapy for chronic refractory coccidioidomycosis

21 January 2018

1 reference

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

Simultaneous high-performance liquid chromatographic determination of SCH 59884 (phosphate ester prodrug of SCH 56592), SCH 207962 and SCH 56592 in dog plasma

21 January 2018

1 reference

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.

21 January 2018

1 reference

Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L005

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18713852%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017